 Marker Therapeutics Inc NASDAQ: MRKR shares are trading lower after Roth Capital downgrades the company from Buy to Neutral and lowers the price target from 3 to 1. The company reported initial results from the Phase 2 trial for MT-401 as a treatment option for Acute myeloid leukemia AML in the post-transplant setting. 